Rhythm Pharmaceuticals (RYTM) Non Operating Income (2016 - 2026)

Rhythm Pharmaceuticals (RYTM) has 11 years of Non Operating Income data on file, last reported at -$2.7 million in Q1 2026.

• On a quarterly basis, Non Operating Income fell 13.21% year-over-year to -$2.7 million in Q1 2026; TTM through Mar 2026 was -$4.3 million, a 207.15% decrease from a year earlier, with the FY2025 full-year figure at -$4.0 million, down 176.73% from the prior year.
• Non Operating Income for Q1 2026 stood at -$2.7 million, down from -$473000.0 in the prior quarter.
• Over the last five years, Non Operating Income for RYTM reached as high as $8.7 million in Q2 2024 and fell as low as -$2.7 million in Q1 2026.
• Historically, Non Operating Income has averaged -$188117.6 across 5 years, with a median of -$172000.0 in 2023.
• Across the five-year window, Non Operating Income slumped 1255.07% in 2022 and soared 8883.84% in 2024, its largest moves.
• Year by year, Non Operating Income stood at -$390000.0 in 2022, then surged by 55.9% to -$172000.0 in 2023, then plunged by 1136.63% to -$2.1 million in 2024, then surged by 77.76% to -$473000.0 in 2025, then slumped by 477.8% to -$2.7 million in 2026.
• Per Business Quant data, the three most recent Non Operating Income figures were -$2.7 million in Q1 2026, -$473000.0 in Q4 2025, and -$140000.0 in Q3 2025.